AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28391418 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin-containing quadruple therapy (esomeprazole 20 mg twice/day, amoxicillin 1000 mg twice/day, levofloxacin 500 mg once/day, bismuth 220 mg twice/day for 14 days)
Number of subjects: 400
Study 28391418 — intervention group
Group type: COMPARATOR
Intervention: Cefuroxime-containing quadruple therapy (esomeprazole 20 mg twice/day, cefuroxime 500 mg twice/day, levofloxacin 500 mg once/day, bismuth 220 mg twice/day for 14 days)
Number of subjects: 400
Study 26362666 — intervention group
Group type: EXPERIMENTAL
Intervention: Vancomycin
Number of subjects: 252
Study 26362666 — intervention group
Group type: COMPARATOR
Intervention: Trimethoprim-sulfamethoxazole (TMP-SMX)
Number of subjects: 252
Study 26362666 — intervention group
Group type: EXPERIMENTAL
Intervention: Included patients
Number of subjects: 252
Study 26362666 — intervention group
Group type: COMPARATOR
Intervention: Excluded patients
Number of subjects: 252
Study 24187860 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture and moxibustion at Baihui (GV 20), Sishencong (EX‐HN 1), Shenmai (BL 62), and Zhaohai (KI 6)
Number of subjects: 120
Study 24187860 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture at Shenmen (HT 7), Neiguan (PC 6), and Sanyinjiao (SP 6)
Number of subjects: 120
Study 22075818 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine + adrenaline
Number of subjects: 40
Study 22075818 — intervention group
Group type: COMPARATOR
Intervention: Adrenaline only
Number of subjects: 40
Study 19656771 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary energy restriction (DER) - liquid diet, 3,656 kJ/d (864 kcal/d); n = 10
Number of subjects: 19
Study 19656771 — intervention group
Group type: COMPARATOR
Intervention: Normal eating patterns; n = 9
Number of subjects: 19
Study 17426677 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of simvastatin and aspirin
Number of subjects: 263
Study 17426677 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 263
Study 12759560 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 mg triazolam (TRZ)
Number of subjects: 10
Study 12759560 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 mg brotizolam (BRZ)
Number of subjects: 10
Study 12759560 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.125 mg triazolam (TRZ)
Number of subjects: 10
Study 12759560 — intervention group
Group type: COMPARATOR
Intervention: placebo (PLA)
Number of subjects: 10
Study 11040171 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical amethocaine gel (1.5 g applied to the dorsum of either foot)
Number of subjects: 56
Study 11040171 — intervention group
Group type: COMPARATOR
Intervention: Placebo (1.5 g applied to the dorsum of either foot)
Number of subjects: 56
Study 8836336 — intervention group
Group type: EXPERIMENTAL
Intervention: Mizolastine (10 mg once daily)
Number of subjects: 56
Study 8836336 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 1428312 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac (3 x 50 mg for 6 weeks)
Number of subjects: 158
Study 1428312 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 158
Study 1428312 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac
Number of subjects: 158
Study 6239398 — intervention group
Group type: EXPERIMENTAL
Intervention: Bypass procedures
Number of subjects: 201
Study 6239398 — intervention group
Group type: COMPARATOR
Intervention: Amputation
Number of subjects: 201
Study 3553279 — intervention group
Group type: EXPERIMENTAL
Intervention: L-649,923
Number of subjects: 12
Study 3553279 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 29448136 — intervention group
Group type: EXPERIMENTAL
Intervention: DBT + DBT PE
Number of subjects: 26
Study 29448136 — intervention group
Group type: COMPARATOR
Intervention: DBT
Number of subjects: 26
Study 29448136 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 26
Study 27721995 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensory Enrichment Therapy
Number of subjects: 1002
Study 24191870 — intervention group
Group type: EXPERIMENTAL
Intervention: Fuji I, glass ionomer (GI)
Number of subjects: 35
Study 24191870 — intervention group
Group type: EXPERIMENTAL
Intervention: Rely X Unicem, self-adhesive cement (SA)
Number of subjects: 35
Study 24191870 — intervention group
Group type: COMPARATOR
Intervention: Adhesor, zinc phosphate cement (ZPh)
Number of subjects: 35
Study 24191870 — intervention group
Group type: COMPARATOR
Intervention: Panavia F 2.0, resin cement
Number of subjects: 35
Study 24191870 — intervention group
Group type: EXPERIMENTAL
Intervention: Fuji Plus, resin-modified glass ionomer (RMGI)
Number of subjects: 35
Study 22108523 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Number of subjects: 338
Study 20016012 — intervention group
Group type: EXPERIMENTAL
Intervention: High-energy-density (HED) snack food (60g daily for 14 days)
Number of subjects: 53
Study 20016012 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-energy-density (LED) snack food (60g daily for 14 days)
Number of subjects: 53
Study 18089623 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg of sulodexide
Number of subjects: 149
Study 18089623 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg of sulodexide
Number of subjects: 149
Study 18089623 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 149
Study 17108871 — intervention group
Group type: EXPERIMENTAL
Intervention: Various medical strategies for weight loss (dietary intervention, physical activity, behavior modification, pharmacotherapy, surgery)
Number of subjects: 0
Study 17108871 — intervention group
Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 0
Study 14604717 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg oral clorazepate dipotassium
Number of subjects: 97
Study 14604717 — intervention group
Group type: COMPARATOR
Intervention: 1 mg intravenous midazolam
Number of subjects: 97
Study 10924737 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 305
Study 10924737 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 305
Study 8810584 — intervention group
Group type: EXPERIMENTAL
Intervention: Small stimulus (S)
Number of subjects: 0
Study 8810584 — intervention group
Group type: EXPERIMENTAL
Intervention: Large stimulus (L)
Number of subjects: 0
Study 8810584 — intervention group
Group type: COMPARATOR
Intervention: SLLL sequences
Number of subjects: 0
Study 8810584 — intervention group
Group type: EXPERIMENTAL
Intervention: LSSS sequences
Number of subjects: 0
Study 1430679 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination thrombolytic therapy (rt-PA and urokinase)
Number of subjects: 287
Study 1430679 — intervention group
Group type: EXPERIMENTAL
Intervention: Urokinase monotherapy
Number of subjects: 287
Study 1430679 — intervention group
Group type: COMPARATOR
Intervention: rt-PA monotherapy
Number of subjects: 287
Study 1430679 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination thrombolytic therapy
Number of subjects: 287
Study 6374780 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine (1 mg daily for five days a week)
Number of subjects: 75
Study 6374780 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid therapy
Number of subjects: 75
Study 30394988 — intervention group
Group type: EXPERIMENTAL
Intervention: Local excision
Number of subjects: 321
Study 30394988 — intervention group
Group type: COMPARATOR
Intervention: Radical resection
Number of subjects: 321
Study 30187524 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% dextrose (D5W) injection, 5ml
Number of subjects: 54
Study 30187524 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroid (triamcinolone acetonide) injection, 3ml mixed with 2ml normal saline
Number of subjects: 54
Study 27927219 — intervention group
Group type: EXPERIMENTAL
Intervention: Reference to an earlier systematic review with additional randomised trials
Number of subjects: 101
Study 27927219 — intervention group
Group type: EXPERIMENTAL
Intervention: Reference to an earlier systematic review without additional trials
Number of subjects: 101
Study 27927219 — intervention group
Group type: EXPERIMENTAL
Intervention: Reference to randomised trials in isolation
Number of subjects: 101
Study 27927219 — intervention group
Group type: EXPERIMENTAL
Intervention: Explicit justification for the proposed randomised trial on the basis of being the first to address the research question
Number of subjects: 101
Study 27927219 — intervention group
Group type: COMPARATOR
Intervention: A randomised controlled trial was not cited
Number of subjects: 101
Study 27927219 — intervention group
Group type: COMPARATOR
Intervention: A systematic review was cited but did not inform trial design
Number of subjects: 101
Study 24015666 — intervention group
Group type: EXPERIMENTAL
Intervention: Bucketball (3 vs. 3 and 6 vs. 6)
Number of subjects: 10
Study 24015666 — intervention group
Group type: EXPERIMENTAL
Intervention: Bucketball (6 vs. 6)
Number of subjects: 10
Study 22899707 — intervention group
Group type: EXPERIMENTAL
Intervention: community-coordinated, victim-focused outreach program
Number of subjects: 236
Study 20819631 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05 microg x kg(‐1) x h(‐1) naloxone (group II)
Number of subjects: 80
Study 20819631 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 microg x kg(‐1) x h(‐1) naloxone (group III)
Number of subjects: 80
Study 20819631 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 microg x kg(‐1) x h(‐1) naloxone (group IV)
Number of subjects: 80
Study 20819631 — intervention group
Group type: COMPARATOR
Intervention: Control group (no naloxone, group I)
Number of subjects: 80
Study 17972359 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone 6 mg/day plus selegiline 10 mg/day (5 mg bid)
Number of subjects: 40
Study 17972359 — intervention group
Group type: COMPARATOR
Intervention: Risperidone 6 mg/day plus placebo
Number of subjects: 40
Study 15948609 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid presentation (150 ms/item)
Number of subjects: 0
Study 15948609 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow presentation (500 ms/item)
Number of subjects: 0
Study 15948609 — intervention group
Group type: EXPERIMENTAL
Intervention: Both rapid and slow presentations
Number of subjects: 0
Study 12955641 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose liposomal amphotericin B (L-AmB) 7.5 mg/kg
Number of subjects: 203
Study 10735688 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of mannitol, furosemide, and dopamine (group B)
Number of subjects: 100
Study 10735688 — intervention group
Group type: COMPARATOR
Intervention: Intermittent doses of diuretics (furosemide, bumetadine, and ethracrynic acid) and fluids (group A)
Number of subjects: 100
Study 8716750 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of morphine (CIM)
Number of subjects: 40
Study 8716750 — intervention group
Group type: COMPARATOR
Intervention: Intermittent intramuscular injection of pethidine (IMP)
Number of subjects: 40
Study 8716750 — intervention group
Group type: EXPERIMENTAL
Intervention: CIM and IMP
Number of subjects: 40
Study 1350804 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonoxynol-9 (N-9) with condoms
Number of subjects: 343
Study 1350804 — intervention group
Group type: COMPARATOR
Intervention: Condoms only (placebo)
Number of subjects: 343
Study 4006549 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone pretreatment
Number of subjects: 6
Study 4006549 — intervention group
Group type: COMPARATOR
Intervention: Placebo pretreatment
Number of subjects: 6
Study 4006549 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term intravenous naloxone administration
Number of subjects: 6
Study 30702403 — intervention group
Group type: EXPERIMENTAL
Intervention: Bleaching treatment with room temperature storage (21.04°C±3.13°C)
Number of subjects: 30
Study 30702403 — intervention group
Group type: COMPARATOR
Intervention: Bleaching treatment with refrigerated storage (5°C)
Number of subjects: 30
Study 30702403 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective evaluation using Vita Classic
Number of subjects: 30
Study 30702403 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective evaluation using Vita Bleachedguide
Number of subjects: 30
Study 30702403 — intervention group
Group type: EXPERIMENTAL
Intervention: Objective evaluation using Vita Easyshade spectrophotometer
Number of subjects: 30
Study 30702403 — intervention group
Group type: EXPERIMENTAL
Intervention: Consistency test of bleaching gels
Number of subjects: 30
Study 28034564 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 ml black tea
Number of subjects: 20
Study 28034564 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 27535435 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous Chondrocyte Implantation (ACI)
Number of subjects: 80
Study 27535435 — intervention group
Group type: COMPARATOR
Intervention: Microfracture
Number of subjects: 80
Study 27535435 — intervention group
Group type: EXPERIMENTAL
Intervention: Surviving patients in ACI group
Number of subjects: 80
Study 27535435 — intervention group
Group type: COMPARATOR
Intervention: Surviving patients in microfracture group
Number of subjects: 80
Study 24065124 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG‐IFN/RBV combination therapy
Number of subjects: 326
Study 21972425 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (250 mg)
Number of subjects: 14
Study 21972425 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 21190455 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative care management by a medically supervised nurse
Number of subjects: 214
Study 21190455 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 214
Study 18715200 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin detemir
Number of subjects: 476
Study 18715200 — intervention group
Group type: COMPARATOR
Intervention: NPH insulin
Number of subjects: 476
Study 15704420 — intervention group
Group type: EXPERIMENTAL
Intervention: Dichotic pitch stimulus
Number of subjects: 11
Study 15704420 — intervention group
Group type: EXPERIMENTAL
Intervention: Active response to stimuli
Number of subjects: 11
Study 15704420 — intervention group
Group type: COMPARATOR
Intervention: Control stimuli
Number of subjects: 11
Study 15704420 — intervention group
Group type: COMPARATOR
Intervention: Ignored random stimuli while watching silent cartoons
Number of subjects: 11
Study 12552319 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotonic % 0.9 saline (Group 1)
Number of subjects: 80
Study 12552319 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% glucose solutions (Group 2)
Number of subjects: 80
Study 12552319 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group 3)
Number of subjects: 80
Study 10601539 — intervention group
Group type: EXPERIMENTAL
Intervention: Ornithine alpha-ketoglutarate (20 g/day)
Number of subjects: 60
Study 10601539 — intervention group
Group type: COMPARATOR
Intervention: Isocaloric placebo
Number of subjects: 60
Study 8835632 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalational anaesthesia (isoflurane)
Number of subjects: 30
Study 8835632 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuroleptoanalgesia
Number of subjects: 30
Study 8835632 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anaesthesia
Number of subjects: 30
Study 2206833 — intervention group
Group type: EXPERIMENTAL
Intervention: Michel clips
Number of subjects: 50
Study 2206833 — intervention group
Group type: COMPARATOR
Intervention: Interrupted monofilament nylon sutures
Number of subjects: 50
Study 6107100 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 0
Study 6107100 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunitrazepam
Number of subjects: 0
Study 6107100 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline
Number of subjects: 0
Study 31113476 — intervention group
Group type: EXPERIMENTAL
Intervention: Re‐Join®
Number of subjects: 53
Study 31113476 — intervention group
Group type: COMPARATOR
Intervention: HA (Hyaluronic Acid)
Number of subjects: 53
Study 28720029 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation Response (RR)
Number of subjects: 0
Study 28720029 — intervention group
Group type: COMPARATOR
Intervention: Control (wait-list)
Number of subjects: 0
Study 25668399 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised progressive impact exercise program three times a week for 12 months (n = 40)
Number of subjects: 80
Study 25668399 — intervention group
Group type: COMPARATOR
Intervention: Nonintervention control group (n = 40)
Number of subjects: 80
Study 24083027 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment (twice a week for eight weeks)
Number of subjects: 20
Study 21713577 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior hiatal repair
Number of subjects: 102
Study 21713577 — intervention group
Group type: COMPARATOR
Intervention: Posterior hiatal repair
Number of subjects: 102
Study 19878027 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT)
Number of subjects: 21
Study 19878027 — intervention group
Group type: COMPARATOR
Intervention: No laser irradiation (control group)
Number of subjects: 21
Study 16968580 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab add-on therapy
Number of subjects: 419
Study 16968580 — intervention group
Group type: COMPARATOR
Intervention: Standard Therapy (ST)
Number of subjects: 419
Study 12534583 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 1000 mg
Number of subjects: 638
Study 12534583 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 500 mg
Number of subjects: 638
Study 12534583 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol 1000 mg
Number of subjects: 638
Study 12534583 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol 500 mg
Number of subjects: 638
Study 12534583 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 638
Study 10772374 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention by ambulatory care clinical pharmacists
Number of subjects: 523
Study 10772374 — intervention group
Group type: EXPERIMENTAL
Intervention: In-person contacts
Number of subjects: 523
Study 9037323 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylephrine (1 microgram/kg) infusion
Number of subjects: 16
Study 9037323 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside (1 microgram/kg) infusion
Number of subjects: 16
Study 8584604 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertonic saline infusion (5% sodium chloride at 0.06 ml/kg/min)
Number of subjects: 21
Study 8584604 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion (0.9% sodium chloride at 0.06 ml/kg/min)
Number of subjects: 21
Study 2670535 — intervention group
Group type: EXPERIMENTAL
Intervention: ACC‐9653 (PHT prodrug) administered intravenously (i.v.)
Number of subjects: 43
Study 2670535 — intervention group
Group type: EXPERIMENTAL
Intervention: ACC‐9653 (PHT prodrug) administered intramuscularly (i.m.)
Number of subjects: 43
Study 2670535 — intervention group
Group type: COMPARATOR
Intervention: Comparison of area under curve (AUC) ratio of PHT after i.m. and i.v. ACC‐9653
Number of subjects: 43
Study 324279 — intervention group
Group type: EXPERIMENTAL
Intervention: Amikacin plus penicillin (A+P)
Number of subjects: 117
Study 324279 — intervention group
Group type: COMPARATOR
Intervention: Amikacin plus carbenicillin (A+C)
Number of subjects: 117
Study 324279 — intervention group
Group type: EXPERIMENTAL
Intervention: Synergistic combinations
Number of subjects: 117
Study 324279 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacteremic patients
Number of subjects: 117
Study 324279 — intervention group
Group type: EXPERIMENTAL
Intervention: High bactericidal activity (≥ 1/8)
Number of subjects: 117
Study 29656669 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitated tucking position
Number of subjects: 40
Study 29656669 — intervention group
Group type: COMPARATOR
Intervention: Routine position
Number of subjects: 40
Study 29911793 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal support
Number of subjects: 1000
Study 29911793 — intervention group
Group type: EXPERIMENTAL
Intervention: Neighborhood support
Number of subjects: 1000
Study 25814428 — intervention group
Group type: EXPERIMENTAL
Intervention: Six different moistening solutions (specific solutions not detailed)
Number of subjects: 58
Study 24372155 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast ice cream consumption (5 min)
Number of subjects: 3
Study 24372155 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow ice cream consumption (30 min)
Number of subjects: 3
Study 21734976 — intervention group
Group type: EXPERIMENTAL
Intervention: EDSC (Excite DSC)/V
Number of subjects: 105
Study 21734976 — intervention group
Group type: EXPERIMENTAL
Intervention: EDSC-V LC (One Shot)
Number of subjects: 105
Study 21734976 — intervention group
Group type: COMPARATOR
Intervention: Variolink II (V)
Number of subjects: 105
Study 21734976 — intervention group
Group type: COMPARATOR
Intervention: V light‐cured (LC)
Number of subjects: 105
Study 21734976 — intervention group
Group type: COMPARATOR
Intervention: Excite LC (ELC)/V
Number of subjects: 105
Study 21734976 — intervention group
Group type: EXPERIMENTAL
Intervention: ELC/V LC
Number of subjects: 105
Study 21734976 — intervention group
Group type: EXPERIMENTAL
Intervention: ELC‐V LC (One Shot)
Number of subjects: 105
Study 19221352 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid-acting insulin analogues (insulin lispro)
Number of subjects: 117
Study 19221352 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid-acting insulin analogues (insulin aspart)
Number of subjects: 117
Study 19221352 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid-acting insulin analogues (insulin lispro) in type 2 diabetes
Number of subjects: 117
Study 19221352 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid-acting insulin analogues (insulin aspart) in type 2 diabetes
Number of subjects: 117
Study 19221352 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting insulin analogues (insulin glargine)
Number of subjects: 117
Study 19221352 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting insulin analogues (insulin detemir)
Number of subjects: 117
Study 19221352 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting insulin analogues (insulin glargine) in type 2 diabetes
Number of subjects: 117
Study 19221352 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting insulin analogues (insulin detemir) in type 2 diabetes
Number of subjects: 117